# US 2023/0407307 A1 · Modified antisense oligonucleotides targeting splicing factors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407307 A1
- Document ID: US20230407307A1
- Status: Published application
- Kind: A1
- Application number: 18/035,319
- Filed: 2021-11-04
- Published: 2023-12-21
- Earliest claimed: 2020-11-05
- Assignees: The Jackson Laboratory
- Applicants: The Jackson Laboratory
- Inventors: Olga Anczuków-Camarda; Nathan Leclair
- Web page: https://patentgrep.com/patent/US20230407307A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/33: Alteration of splicing
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are chemically modified antisense oligonucleotides that bind to sequences on mRNAs encoding the splicing factor TKA2β, associated with cancer.

## Claims

### Claim 1

An antisense oligonucleotide comprising a sequence that binds to a target sequence on an mRNA that encodes TRA2β, wherein the antisense oligonucleotide further comprises a 2′-O-methoxyethyl modification.

### Claim 2 (depends on 1)

The antisense oligonucleotide of claim 1, wherein at least 80% of the nucleotides of the antisense oligonucleotide comprise a 2′-O-methoxyethyl modification.

### Claim 3 (depends on 1, 2)

The antisense oligonucleotide of claim 1 or 2, wherein each of the nucleotides of the antisense oligonucleotide comprises 2′-O-methoxyethyl modification.

### Claim 4 (depends on 1, 2, 3)

The antisense oligonucleotide of any one of claims 1-3, further comprising a phosphorothioate modification.

### Claim 5 (depends on 4)

The antisense oligonucleotide of claim 4, wherein at least 80% of the internucleoside phosphates of the antisense oligonucleotide comprise a phosphorothioate modification.

### Claim 6 (depends on 4, 5)

The antisense oligonucleotide of claim 4 or 5, wherein each of the internucleoside phosphates of the antisense oligonucleotide comprise a phosphorothioate modification.

### Claim 7 (depends on 1, 2, 3)

The antisense oligonucleotide of any one of claims 1-3, wherein each of the nucleotides of the antisense oligonucleotide comprises a 2′-O-methoxyethyl modification, and each of the internucleoside phosphates of the antisense oligonucleotide comprises a phosphorothioate modification.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The antisense oligonucleotide of any one of claims 1-7, wherein the target sequence is within an intronic splicing silencer sequence.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antisense oligonucleotide of any one of claims 1-8, wherein the target sequence comprises a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 2.

### Claim 10 (depends on 9)

The antisense oligonucleotide of claim 9, wherein the target sequence comprises a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 2.

### Claim 11 (depends on 10)

The antisense oligonucleotide of claim 10, wherein the target sequence comprises the sequence of SEQ ID NO: 2.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The antisense oligonucleotide of any one of claims 1-11, wherein the oligonucleotide comprises a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 3.

### Claim 13 (depends on 12)

The antisense oligonucleotide of claim 12, wherein the oligonucleotide comprises a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 3.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The antisense oligonucleotide of any one of claims 1-13, comprising no more than two nucleotide substitutions relative to the sequence of SEQ ID NO: 3.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The antisense oligonucleotide of any one of claims 1-14, comprising no more than one nucleotide substitution relative to the sequence of SEQ ID NO: 3.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The antisense oligonucleotide of claim any one of claims 1-15, wherein the oligonucleotide comprises the sequence of SEQ ID NO: 3.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The antisense oligonucleotide of any one of claims 1-16, wherein binding of the antisense oligonucleotide increases TRA2β-PE inclusion and/or decreases TRA2β protein expression by at least 30% relative to a non-targeting control antisense oligonucleotide.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The antisense oligonucleotide of claim 1-17 formulated in a delivery vehicle.

### Claim 19 (depends on 18)

The antisense oligonucleotide of claim 18, wherein the delivery vehicle is a cationic lipid nanoparticle.

### Claim 20 (depends on 18)

The antisense oligonucleotide of claim 18, wherein the delivery vehicle is a liposome.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A delivery vector comprising the antisense oligonucleotide of any one of claims 1-12.

### Claim 22 (depends on 21)

The delivery vector of claim 21, wherein the delivery vector is a viral vector.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A host cell comprising the antisense oligonucleotide of any one of claims 1-20 or the delivery vector of claim 21 or 22.

### Claim 24 (depends on 23)

The host cell of claim 23, wherein the host cell is a cancer cell, optionally a breast cancer cell, such as a triple-negative breast cancer cell, an ovarian cancer cell, a colon cancer cell, a glioblastoma cell, a bladder cancer cell, a kidney cancer cell, a liver cancer cell, a lung cancer cell, or a prostate cancer cell.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A pharmaceutical composition comprising the antisense oligonucleotide of any one of claims 1-20, or the delivery vector of claim 21, and a pharmaceutically acceptable excipient.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25)

A method comprising administering to a subject the antisense oligonucleotide of any one of claims 1-20 or the pharmaceutical composition of claim 25.

### Claim 27 (depends on 26)

The method of claim 26, wherein the subject has breast cancer, ovarian cancer, colon cancer, glioblastoma, bladder cancer, kidney cancer, liver cancer, lung cancer, or prostate cancer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the subject has triple-negative breast cancer.

### Claim 29 (depends on 26, 27, 28)

The method of any one of claims 26-28, wherein the administering is intravenous, intramuscular, intraperitoneal, subcutaneous, intranasal, or intratumoral.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method comprising synthesizing the antisense oligonucleotide of any one of claims 1-20.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method comprising formulating the antisense oligonucleotide of any one of claims 1-20 with a pharmaceutically acceptable excipient.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25)

A kit comprising the antisense oligonucleotide of any one of claims 1-20 or the pharmaceutical composition of claim 25, and a delivery device.
